Valuation
- Market cap
- 430,000
- Revenue TTM
- $0
- Net income TTM
- $-19,920,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- -0.02
Trading
- Volume
- 534,600
- Avg volume
- 624,040
- Day's range
- $0.01 – $0.01
- Shares out
- 71,631,000
- Stochastic %K
- 14%
- Beta
- 0.19
- Analysts
- Strong Buy
- Price target
- $30.00
Company profile
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 407 2376
- Website
- https://www.cero.bio
- Address
- 201 Haskins Way, Suite 230, South San Francisco, United States
Latest news
No headlines yet.
